摘要
目的分析度普利尤单抗治疗特异性皮炎(AD)的临床价值。方法47例AD患者为研究对象,依据随机数字表法分为观察组(24例)与对照组(23例)。对照组采用常规用药治疗,观察组在对照组基础上采用度普利尤单抗治疗。对比两组治疗效果、临床症状缓解时间、症状评分、不良反应发生及复发情况。结果观察组治疗总有效率95.83%高于对照组的69.57%,差异有统计学意义(P<0.05)。观察组皮损、皮肤瘙痒缓解时间分别为(7.77±1.89)、(5.10±0.62)d,均短于对照组的(10.65±2.44)、(7.72±0.81)d,差异有统计学意义(P<0.05)。治疗后,观察组特应性皮炎积分指数(SCORAD)、视觉模拟评分法(VAS)评分分别为(35.42±9.72)、(4.12±1.16)分,均低于对照组的(48.52±8.34)、(6.13±1.32)分,差异有统计学意义(P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。观察组疾病复发率为0,低于对照组的26.09%,差异有统计学意义(P<0.05)。结论度普利尤单抗在AD治疗中有助于减轻患者临床症状,复发率低,具有安全性,临床效果显著,值得推广应用。
Objective To analyze the clinical value of dupilumab in the treatment of atopic dermatitis(AD).Methods A total of 47 AD patients were divided into observation group(24 cases)and control group(23 cases)according to random numerical table.The control group was treated with conventional medication,and the observation group was treated with dupilumab on the basis of the control group.The therapeutic effect,clinical symptom relief time,symptom score,occurrence of adverse reactions and recurrence were compared between the two groups.Results The total effective rate of the observation group was 95.83%,which was higher than 69.57%of the control group,and the difference was statistically significant(P<0.05).The relief time of skin lesions and itch in the observation group were(7.77±1.89)and(5.10±0.62)d,which were shorter than(10.65±2.44)and(7.72±0.81)d in the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of scoring atopic dermatitis index(SCORAD)score and visual analogue scale(VAS)score in the observation group were(35.42±9.72)and(4.12±1.16)points,which were lower than(48.52±8.34)and(6.13±1.32)points in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).The recurrence rate of the observation group was 0%,which was lower than 26.09%of the control group,and the differences were statistically significant(P<0.05).Conclusion Dupilumab can help reduce the clinical symptoms of patients with AD,with less adverse reactions,high safety,low recurrence rate,and significant clinical effect,which is worthy of promotion and application.
作者
王晓红
WANG Xiao-hong(Department of Dermatology,Xinyi People's Hospital,Xinyi 221400,China)
出处
《中国现代药物应用》
2022年第24期145-147,共3页
Chinese Journal of Modern Drug Application
